

Meningitis - Pipeline Review, H2 2019

<https://marketpublishers.com/r/MDF3A2AF146EN.html>

Date: December 2019

Pages: 67

Price: US\$ 2,000.00 (Single User License)

ID: MDF3A2AF146EN

Abstracts

Meningitis - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meningitis - Pipeline Review, H2 2019, provides an overview of the Meningitis (Infectious Disease) pipeline landscape.

'Meningitis is the inflammation caused by viruses and bacteria on the protective membranes covering the brain and spinal cord. The cause of inflammation can be infection by viruses, bacteria, or other microorganisms, and less commonly by certain drugs. As the inflammation is in proximity to the brain and spinal cord, meningitis can be life threatening.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meningitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Meningitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meningitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Meningitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Meningitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Meningitis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Meningitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Meningitis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Meningitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Meningitis (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Meningitis (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Meningitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Meningitis - Overview
- Meningitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Meningitis - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Meningitis - Companies Involved in Therapeutics Development
 - CanSino Biologics Inc
 - Chongqing Zhifei Biological Products Co Ltd
 - Eubiologics Co Ltd
 - Matinas BioPharma Holdings Inc
 - Mycovia Pharmaceuticals Inc
 - Olymvax Biopharmaceuticals Inc
 - Pneumagen Ltd
 - TGV Therapeutics
 - Yisheng Biopharma Co Ltd
- Meningitis - Drug Profiles
 - (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - (Haemophilus influenzae type b + rotavirus) vaccine - Drug Profile
 - Product Description
 - Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSB-015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EUC-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningitis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

meningococcal [serotypes A, C] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MYC-053 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neumifil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal [serotype 4, 6A] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Cryptococcal Meningitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1129 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1598 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Meningitis - Dormant Projects

Meningitis - Discontinued Products

Meningitis - Product Development Milestones

Featured News & Press Releases

Oct 14, 2019: Matinas BioPharma initiates EnACT study of MAT2203 (Oral Amphotericin B) for the treatment of fungal cryptococcal meningitis

Oct 07, 2019: Matinas BioPharma receives orphan drug designation from U.S. FDA for MAT2203 for the treatment of cryptococcosis

Jul 25, 2019: Matinas BioPharma receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis

Jun 03, 2019: Matinas BioPharma to present on MAT2203 at the 9th Annual LD Micro Invitational

May 28, 2019: Matinas BioPharma announces publication of MAT2203 Preclinical Cryptococcal Meningitis data in the American Society for Microbiology Journal, mBio

May 01, 2019: Matinas BioPharma selected to present at the BioNJ Ninth Annual BioPartnering Conference

Dec 20, 2018: Matinas BioPharma to present data on MAT2203 at Biotech Showcase 2019

Aug 08, 2017: Matinas BioPharma Reaffirms Clinical and Regulatory Strategy to Advance MAT2203

Jun 02, 2017: Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis

May 30, 2017: Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology's ASM

Microbe 2017 Conference

Jun 16, 2016: Clinical Trial of Phase III of Group A and Group C Meningococcal Conjugate vaccine Phase III Clinical Trial Initiated

Jun 01, 2016: Viamet Receives Fast Track Designation from the FDA for VT-1129 for the Treatment of Cryptococcal Meningitis

Sep 16, 2015: FDA Grants QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis

Jun 29, 2015: Olymvax obtains Chinese approval for clinical trials of Meningococcal conjugate vaccine

Apr 24, 2015: Viamet to Provide Update on VT-1129, Novel Antifungal Program at ECCMID 2015

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Meningitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Meningitis - Pipeline by CanSino Biologics Inc, H2 2019
Meningitis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2019
Meningitis - Pipeline by Eubiologics Co Ltd, H2 2019
Meningitis - Pipeline by Matinas BioPharma Holdings Inc, H2 2019
Meningitis - Pipeline by Mycovia Pharmaceuticals Inc, H2 2019
Meningitis - Pipeline by Olymvax Biopharmaceuticals Inc, H2 2019
Meningitis - Pipeline by Pneumagen Ltd, H2 2019
Meningitis - Pipeline by TGV Therapeutics, H2 2019
Meningitis - Pipeline by Yisheng Biopharma Co Ltd, H2 2019
Meningitis - Dormant Projects, H2 2019
Meningitis - Dormant Projects, H2 2019 (Contd..1), H2 2019
Meningitis - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Meningitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

CanSino Biologics Inc
Chongqing Zhifei Biological Products Co Ltd
Eubiologics Co Ltd
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals Inc
Olymvax Biopharmaceuticals Inc
Pneumagen Ltd
TGV Therapeutics
Yisheng Biopharma Co Ltd

I would like to order

Product name: Meningitis - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/MDF3A2AF146EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MDF3A2AF146EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970